Anti-skeletal muscle and anti-acetylcholine receptor antibodies in patients with thymoma without myasthenia gravis: relation to the onset of myasthenia gravis. 1991

M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
Clinical Research Center, Utano National Hospital, Kyoto, Japan.

We measured the anti-skeletal muscle (SM) antibody titers in sera from 46 patients with thymoma but without Myasthenia gravis (MG) in order to determine whether the presence of anti-SM antibody is linked to the combination of thymoma-MG, or to thymoma alone. We detected anti-SM antibodies in 18 of these sera, of which 15 had concomitantly elevated titers of anti-AChR antibodies. Moreover, 9 of whom had experienced the onset of MG after surgery. In contrast, no patient without elevations in both antibodies developed MG during the followup. We conclude that the presence of anti-SM antibodies is linked strongly with thymoma associated with MG, but not with thymoma alone.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
February 1980, Neurology,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
March 2011, Journal of the neurological sciences,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
August 2008, Neuromuscular disorders : NMD,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
January 2009, Frontiers of neurology and neuroscience,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
January 2014, Muscle & nerve,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
May 1981, Italian journal of neurological sciences,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
May 1998, Annals of the New York Academy of Sciences,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
December 1993, Journal of the neurological sciences,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
March 2001, Nature medicine,
M Ohta, and M Itoh, and H Hara, and N Itoh, and H Nishitani, and K Hayashi, and K Ohta
September 1996, Transfusion science,
Copied contents to your clipboard!